drugset / Trial / NCT04416607

Corifollitropin Alpha and Ovarian Response

NCT04416607

Completed 300 enrolled Hospital de Clinicas de Porto Alegre
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Objective: To study whether an administration of corifollitropin alpha modifies the follicular cohort, measured by Follicular Output Rate (FORT), compared to human menopausal gonadotropin (HMG), in infertile patients undergoing in vitro fertilisation (IVF). M/M: 306 infertile patients undergoing in vitro fertilisation (IVF). Ovarian stimulation protocol will be performed with a single dose of 100 μg (\<60kg) or 150 μg (≥60kg) corifollitropin alpha in group 1 (n=147), and 150-300 IU/day human menopausal gonadotropin (HMG) according to age, antimullerian hormone (AMH) level and antral follicle count (AFC) in group 2 (n=150). Moreover, FORT will be calculated as the ratio of pre-ovulatory follicle (16-22 mm in diameter) count on day of HCG×100/small antral follicle (3-8 mm) count at baseline.

Timeline

Start
2018-06-15
Primary completion
2019-01-31
Completion
2019-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 100 ug
Subject Corifollitropin alfa Protein / enzyme biologic 150 ug
Comparator Menopur Protein / enzyme biologic 150 iu
Comparator Menopur Protein / enzyme biologic 300 iu

Indications